Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 November 2022 | Story Andre Damons | Photo Andre Damons
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, Director of Pharmacology in the Department of Pharmacology at the UFS, hosted the first IKS Bio-Trade Indaba, which took place between 24 and 25 November on the Bloemfontein Campus of the UFS.

The inaugural international Indigenous Knowledge and Bio-Trade Indaba, hosted by the University of the Free State (UFS) in collaboration with the Technology Innovation Agency (TIA) – an entity of the Department of Science and Innovation (DSI) – is the ideal platform for various stakeholders to network and share knowledge on current developments in indigenous knowledge research and product development, biodiversity, conservation, innovation, and commercialisation of the IK-based researched products. 

The IKS Bio-Trade Indaba was championed by the university’s African Medicines Innovation and Technology Development Platform (AMITD), which is funded by TIA. AMITD was established to stimulate economic growth by providing science-based solutions and developing technologies that would utilise indigenous knowledge and South African biodiversity to produce high-quality African traditional-medicine-based proprietary products, focusing on priority diseases. AMITD is a national leader in research, development, and formulation research on traditional medicines and has a strong history in IKS research, community collaboration, and participation initiatives, as well as partnerships with industry on herbal medicines.

The indaba, which took place from 24 to 25 November, was a success, opening much-needed dialogue and engagement on the role of IK-based knowledge in research and commercialisation. Going forward, the indaba will be a vital platform to enhance the role of IKS in inclusive development and transformation.

African traditional medicine should be internationally recognised

Prof Motlalepula Matsabisa, Director of Pharmacology in the UFS Department of Pharmacology and AMITD, said he has a special interest in the pharmacology of traditional medicines and that he wants to see more national, continental, and international collaboration so that the dream of making ATM internationally recognised and a global force can be realised. 

“How do we develop new drugs and medicines based on the knowledge we have. We do this without compromising on good all-inclusive science on ATM. We should take the science and put it on the global stage so that all people will begin to respect it,” said Prof Matsabisa. 

According to him, research conducted by AMITD should address national research priorities, community research needs and aspirations to respond to industry research questions and challenges and develop products, intellectual property (IP), as well as commercialisation. “Research needs to have a societal impact and must impact the quality of life of people. We do responsive research that needs to address old diseases, new diseases, neglected diseases, current pandemics, as well as new and re-emerging pandemics.” 

Elevation of IKS profile can no longer be delayed
 
Dr Vuyisile Phehane, Executive: Bio-Economy at the TIA, said the indaba came at a time when the elevation of the profile of IKS can no longer be delayed. TIA acknowledges the rich, largely untapped source of knowledge within communities that has yet to be fully exploited for the economic and social benefit of particularly the underserved regions of the country, and it should be systematically well researched. 

Dr Vuysile Phehane
Dr Phehane, gave a message of support from TIA, saying the indaba came at a time when the elevation of the profile of IKS can no longer be delayed. (Photo: Andre Damons)


“Sectoral support priorities in agriculture, manufacturing, health innovations, and allied health cannot be overlooked, and neither can the various master plans created to support industrial sectors. This thought leadership has a direct bearing on what we are doing here, engaging in dialogue to shape our future, and seeking ways to collaborate and build long-lasting partnerships in the space of IKS. These partnerships not only serve us in the country, but also on the African continent,” said Dr Phehane. 

According to him, TIA played the role of industry builder and sought to increase its efforts to grow and enhance the role of IKS in inclusive development and transformation. The successful commercialisation of all indigenous knowledge-based projects involving the use of indigenous plants requires the capacity to commercially cultivate these plants. 

Dr Phehane said TIA funded AMITD to ensure that the products of promising indigenous knowledge innovations are safe, effective, and of consistently high quality. “This platform seeks to address generations of market failure by bringing IK into the mainstream of commercialisation and truly equitable benefit sharing. Going forward, 20% of our annual MTEF allocation will be channelled towards IK initiatives, which is significant. This is testament to our commitment to IKS.”

The two-day indaba hosted various panel discussions on multiple aspects of IKS research and developments in human and plant health. Among these were discussions on cannabis research to mitigate cancer multidrug resistance, phytoconstituents for the treatment of diabetes, the development of PHELA, a plant-based product as a treatment for COVID-19, natural product-based colon regulator commercialisation, the development of cannabis and other medicinal plants in wound healing and developing hydrogels, as well as the development of IK-based herbal pesticides.

Discussions also focused on new developments in the indigenous health infusion industry, developments in medicine regulations and IK-based clinical trials in South Africa, as well as African medicines research internationalisation. International panellists included Prof Minke Tang (Beijing University of Chinese Medicine), Dr Samuel Obakiro (HOD, Department of Pharmacology, Busitema University, Uganda), and Dr Kofi Donkor (Centre for Plant Medicine Research, Mampong, Ghana), all of whom shared experiences on IKS-related research in their respective countries.

IKS one of the areas targeted for investment and growth 

Dr Glen Taylor, Senior Director: Research Development at the UFS, said the Department of Pharmacology is one of the fastest-growing departments in the Faculty of Health Sciences at the UFS, and attracts a large number of applications from national and international scholars largely due to a very understated Prof Matsabisa.

“We always look at areas where we need to invest in the future and grow, and IKS is one of those areas we targeted and invested in significantly. Through the research and work in IKS, this is done to reposition the institution as a research-led university that is relevant to its communities and societies.” 
The TIA UFS IKS International Indaba was funded by the TIA IKS unit and the Department of Pharmacology – AMITD platform.

News Archive

Carbon dioxide makes for more aromatic decaffeinated coffee
2017-10-27


 Description: Carbon dioxide makes for more aromatic decaffeinated coffee 1b Tags: Carbon dioxide makes for more aromatic decaffeinated coffee 1b 

The Inorganic Group in the Department of Chemistry
at the UFS is systematically researching the utilisation
of carbon dioxide. From the left, are, Dr Ebrahiem Botha,
Postdoctoral Fellow; Mahlomolo Khasemene, MSc student;
Prof André Roodt; Dr Marietjie Schutte-Smith, Senior Lecturer;
and Mokete Motente, MSc student.
Photo: Charl Devenish

Several industries in South Africa are currently producing hundreds of thousands of tons of carbon dioxide a year, which are released directly into the air. A typical family sedan doing around 10 000 km per year, is annually releasing more than one ton of carbon dioxide into the atmosphere.

The Inorganic Chemistry Research Group in the Department of Chemistry at the University of the Free State (UFS), in collaboration with the University of Zurich in Switzerland, has focused in recent years on using carbon dioxide – which is regarded as a harmful and global warming gas – in a meaningful way. 

According to Prof André Roodt, Head of Inorganic Chemistry at the UFS, the Department of Chemistry has for the past five decades been researching natural products that could be extracted from plants. These products are manufactured by plants through photosynthesis, in other words the utilisation of sunlight and carbon dioxide, nitrogen, and other nutrients from the soil.

Caffeine and chlorophyll 
“The Inorganic group is systematically researching the utilisation of carbon dioxide. Carbon dioxide is absorbed by plants through chlorophyll and used to make interesting and valuable compounds and sugars, which in turn could be used for the production of important new medicines,” says Prof Roodt.

Caffeine, a major energy enhancer, is also manufactured through photosynthesis in plants. It is commonly found in tea and coffee, but also (artificially added) in energy drinks. Because caffeine is a stimulant of the central nervous system and reduces fatigue and drowsiness, some people prefer decaffeinated coffee when enjoying this hot drink late at night. 

Removing caffeine from coffee could be expensive and time-consuming, but also environmentally unfriendly, because it involves the use of harmful and flammable liquids. Some of the Inorganic Group’s research focus areas include the use of carbon dioxide for the extraction of compounds, such as caffeine from plants. 

“Therefore, the research could lead to the availability of more decaffeinated coffee products. Although decaffeinated coffee is currently aromatic, we want to investigate further to ensure better quality flavours,” says Prof Roodt.

Another research aspect the team is focusing on is the use of carbon dioxide to extract chlorophyll from plants which have medicinal properties themselves. Chemical suppliers sell chlorophyll at R3 000 a gram. “In the process of investigating chlorophyll, our group discovered simpler techniques to comfortably extract larger quantities from green vegetables and other plants,” says Prof Roodt.

Medicines
In addition, the Inorganic Research Group is also looking to use carbon dioxide as a building block for more valuable compounds. Some of these compounds will be used in the Inorganic Group’s research focus on radiopharmaceutical products for the identification and possibly even the treatment of diseases such as certain cancers, tuberculosis, and malaria.

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept